Denosumab Uptake Could Depend On Abating Physicians’ Financial Risk
Executive Summary
If denosumab is approved, Amgen may need to provide physicians with a shield against the financial risk of stocking the injectable osteoporosis treatment in their offices
You may also be interested in...
Aranesp Declines Put More Pressure On Amgen For Denosumab Success
With sales of Amgen's blockbuster anemia franchise in a freefall and competitive threats to its tumor necrosis factor inhibitor Enbrel looming, the big biotech is banking on the osteoporosis treatment denosumab to drive growth in the years ahead
Aranesp Declines Put More Pressure On Amgen For Denosumab Success
With sales of Amgen's blockbuster anemia franchise in a freefall and competitive threats to its tumor necrosis factor inhibitor Enbrel looming, the big biotech is banking on the osteoporosis treatment denosumab to drive growth in the years ahead
Amgen Hones In On Denosumab Sales And Payer Strategies Ahead Of Launch
Biotech estimates 500 to 1,000 sales reps will be needed to commercialize the osteoporosis injectable in the U.S.